Presence of certain oral bacterium in esophageal cancer samples associated with shorter survival
Bottom Line: Among Japanese patients with esophageal cancer, those whose cancer tested positive for DNA from the bacterium Fusobacterium nucleatum had shorter cancer-specific survival compared with those whose cancer had no DNA from the bacterium.
Journal in Which the Study was Published: Clinical Cancer Research, a journal of the American Association for Cancer Research.
Author: Hideo Baba, MD, PhD, a professor in the Department of Gastroenterological Surgery in the Graduate School of Medical Sciences at Kumamoto University, Japan.
Background: More than 100 trillion bacteria naturally inhabit every person's body; they are collectively referred to as the microbiome, Baba explained.
"The gut microbiome has recently been shown to play an important role in health, as well as in diseases such as obesity, inflammatory bowel disease, diabetes, nonalcoholic fatty liver disease, and several types of cancers," said Baba. "We set out to investigate whether F. nucleatum, which is part of many people's oral microbiome, is associated with esophageal cancer development and/or progression."
How the Study Was Conducted and Results: Baba and colleagues collected esophageal cancer tissue samples from 325 consecutive patients who were having the cancer surgically removed at Kumamoto University Hospital from April 2005 to June 2013 and tested them for the presence of F. nucleatum DNA. Patients were followed until January 31, 2016, or death. During this time, there were 75 deaths attributable to esophageal cancer.
The researchers detected F. nucleatum DNA in 23 percent of the esophageal cancer tissue samples they tested. The presence of F. nucleatum DNA was associated with shorter survival. Specifically, after controlling for factors associated with survival, such as age, tobacco use, and tumor stage, patients with tumors positive for F. nucleatum DNA were significantly more likely to have died as a result of esophageal cancer.
Author Comment: "Our findings suggest that testing for the presence of F. nucleatum DNA in esophageal cancer tissue could provide a biomarker of prognosis," said Baba. "If they are replicated in a large, international, multi-institutional study, such testing could provide physicians with important information to consider while deciding how best to manage the care of a patient with esophageal cancer. In addition, the data suggest that therapeutic targeting of F. nucleatum could be a potential new approach to suppress the development and growth of esophageal cancer.
"It is important to note that our data provide no insight into whether F. nucleatum causes esophageal cancer," added Baba. "However, this is something we are hoping to study in the future."
Limitations: According to Baba, the main limitation of the study is that this is a single-institution study. Because the component bacteria of a person's microbiome differ according to numerous factors, including age, place of residence, food consumed, and race, these data cannot be generalized to all individuals unless they are confirmed in a large, international, multi-institutional study.
Funding & Disclosures: The study was funded in part by SGH Foundation. Baba declares no conflicts of interest.
To interview Hideo Baba, contact Julia Gunther at [email protected] or 215-446-6896.
Follow us: Cancer Research Catalyst http://blog.aacr.org; Twitter @AACR; and Facebook http://www.facebook.com/aacr.org
About the American Association for Cancer Research
Founded in 1907, the American Association for Cancer Research (AACR) is the world's first and largest professional organization dedicated to advancing cancer research and its mission to prevent and cure cancer. AACR membership includes more than 37,000 laboratory, translational, and clinical researchers; population scientists; other health care professionals; and patient advocates residing in 108 countries. The AACR marshals the full spectrum of expertise of the cancer community to accelerate progress in the prevention, biology, diagnosis, and treatment of cancer by annually convening more than 30 conferences and educational workshops, the largest of which is the AACR Annual Meeting with nearly 19,500 attendees. In addition, the AACR publishes eight prestigious, peer-reviewed scientific journals and a magazine for cancer survivors, patients, and their caregivers. The AACR funds meritorious research directly as well as in cooperation with numerous cancer organizations. As the Scientific Partner of Stand Up To Cancer, the AACR provides expert peer review, grants administration, and scientific oversight of team science and individual investigator grants in cancer research that have the potential for near-term patient benefit. The AACR actively communicates with legislators and other policymakers about the value of cancer research and related biomedical science in saving lives from cancer. For more information about the AACR, visit http://www.AACR.org.